Gene Synthesis Market Outlook: Biotechnology Advancements and Growth Opportunities

Rising demand for synthetic genes in drug discovery, vaccine development, and genetic research is driving growth in the gene synthesis market. Expanding applications in synthetic biology, personalized medicine, and industrial biotechnology support adoption. According to IMARC Group's latest research publication, The global gene synthesis market size was valued at USD 2.41 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 9.60 Billion by 2033, exhibiting a CAGR of 15.75% from 2025-2033.

How AI is Reshaping the Future of Gene Synthesis Market

• Automated DNA Design and Error Reduction: AI algorithms analyze sequence complexity and optimize codon usage, reducing synthesis errors by nearly 40% while enhancing fidelity. Machine learning platforms now streamline design workflows, cutting turnaround times significantly.
• Predictive Analytics for Gene Function: AI-powered computational models predict gene expression patterns and protein folding outcomes before physical synthesis. These tools enable researchers to design more effective therapeutic genes, accelerating drug discovery timelines.
• High-Throughput Synthesis Optimization: Artificial intelligence systems control enzymatic synthesis parameters in real-time, monitoring temperature, pH, and reaction kinetics. This automation has improved synthesis throughput by over 30%, making large-scale production more cost-effective.

Explore Updated 2026 Market Trends & Analysis

Gene Synthesis Industry Overview:

The gene synthesis market is experiencing robust expansion driven by breakthroughs in precision medicine and synthetic biology applications. The global precision medicine market reached USD 82.1 billion in 2024, fueling demand for customized DNA sequences. Over one-third of new FDA drug approvals in 2023 involved personalized medicines for the fourth consecutive year, highlighting the pharmaceutical industry's commitment to tailored therapies. Ten gene therapies received FDA approval in 2024—double the previous year—demonstrating accelerating regulatory momentum. These approvals, combined with ongoing mRNA vaccine innovations and CRISPR technology adoption, position gene synthesis as a critical enabler of next-generation therapeutics and diagnostics.

Gene Synthesis Market Trends & Drivers

The rapid advancement of gene therapy and cell-based treatments is fundamentally reshaping the gene synthesis landscape. Pharmaceutical companies are investing heavily in CAR-T cell therapies, viral vector development, and genetic disorder treatments requiring precise synthetic genes. The biopharmaceutical sector commands 46% of market revenue as companies scale up internal programs for monoclonal antibodies, recombinant proteins, and RNA therapeutics. Major players like GenScript reported revenues of USD 594.5 million in 2024, demonstrating strong commercial traction. Government initiatives like ARPA-H funding and the NIH's USD 1.5 million annual commitment to platform technologies accelerate innovation. Academic consortia and translational research partnerships between universities and industry further amplify demand, with academic institutions representing 54% of end-use applications as they conduct foundational genomics research, functional gene studies, and molecular diagnostics development.

Technological innovation is making gene synthesis faster, cheaper, and more accessible across research environments. Next-generation sequencing markets reached USD 23.3 billion in 2024, generating massive datasets that require matching synthetic genes for validation and research. Companies like Twist Bioscience posted USD 92.8 million in quarterly revenue leveraging silicon-based DNA synthesis platforms that improve parallelization and reduce costs. In 2023, GenScript launched GenTitan, the first commercial semiconductor platform for DNA synthesis, achieving the industry's highest acceptance rate for complex sequences at remarkably low prices. Integrated DNA Technologies expanded with a 25,000-square-foot facility in Iowa, doubling its synthetic biology footprint and planning rapid gene synthesis offerings. Cloud-based gene design platforms have reduced turnaround times by 35-40% since 2023, enabling just-in-time synthesis requests. Enzymatic synthesis methods have pushed error rates down nearly 40%, with high-precision products now capturing 52% of the market—critical for therapeutic applications requiring absolute accuracy.

Expanding applications beyond traditional research are creating new revenue streams and market opportunities. Agricultural biotechnology adoption increased 28% across Asia Pacific in 2025, with synthetic genes enabling climate-resistant crops to address food security challenges. Vaccine development surged following mRNA technology success, with DNA Script receiving USD 4.7 million from CEPI to accelerate automated DNA template production supporting the 100 Days Mission. Disease diagnostics now represent a significant application segment as genetic testing becomes mainstream for cancer, rare diseases, and infectious disease detection. Molecular diagnostics and oligonucleotide therapeutics drive collaboration expansions—GenScript announced major oligonucleotide production facility expansions in China during 2023 to meet growing demand. Contract research organizations are forecast to grow fastest at 17.43% as sponsors externalize synthesis to focus on clinical strategy, with GenScript raising USD 224 million specifically for CDMO expansion. Strategic partnerships like Twist Bioscience's 2025 collaboration with Ginkgo Bioworks demonstrate industry consolidation around high-fidelity DNA sequences for bioindustrial manufacturing and pharmaceutical applications.

Leading Companies Operating in the Global Gene Synthesis Industry:

• ATUM
• Boster Biological Technology
• Eurofins Genomics
• Genewiz Inc. (Azenta Life Sciences)
• Genscript Biotech Corp.
• Integrated DNA Technologies Inc.
• Merck KGaA
• OriGene Technologies Inc.
• ProMab Biotechnologies Inc.
• ProteoGenix Inc
• Thermo Fisher Scientific Inc.
• Twist Bioscience

Gene Synthesis Market Report Segmentation:

By Method:

• Solid-Phase Synthesis
• Chip-Based Synthesis
• PCR-Based Enzyme Synthesis

Solid-phase synthesis represents the largest class with over 36.5% market share due to its efficiency, precision, and scalability in creating complex genetic sequences.

By Services:

• Antibody DNA Synthesis
• Viral DNA Synthesis
• Others

Antibody DNA synthesis holds approximately 60.5% of the market owing to increasing demand for monoclonal antibodies in diagnostics and therapeutics.

By Application:

• Gene and Cell Therapy Development
• Vaccine Development
• Disease Diagnosis
• Others

Gene and cell therapy development accounts for over 36.6% market share, driven by breakthroughs in treating genetic disorders and cancers.

By End Use:

• Biotechnology and Pharmaceutical Companies
• Academic and Government Research Institutes
• Contract Research Organizations

Academic and government research institutes represent 54.0% market share due to their central role in advancing genomics and receiving government-backed research funding.

Regional Insights:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America exhibits clear dominance with 39.5% market share due to advanced healthcare infrastructure, strong R&D investments, and presence of major market players.

Recent News and Developments in Gene Synthesis Market

• March 2025: Thermo Fisher Scientific launched its next-generation GeneArt Gene Synthesis Service featuring advanced error correction algorithms and increased throughput capabilities. The platform accelerates synthetic biology workflows with faster turnaround times and enhanced accuracy for therapeutics and vaccine development applications.
• March 2025: Integrated DNA Technologies (IDT) and Elegen announced a strategic partnership to enhance long DNA synthesis capabilities. IDT customers gained early access to Elegen's ENFINIA Plasmid DNA service, enabling rapid delivery of high-complexity clonal genes ranging from 5 kb to 15 kb for cell and gene therapy applications.
• February 2025: CEPI awarded DNA Script USD 4.7 million to accelerate automated DNA template production for mRNA vaccines, supporting the 100 Days Mission for rapid pandemic response capabilities through enzymatic synthesis technology.
• January 2025: Twist Bioscience Corporation announced a strategic partnership with Ginkgo Bioworks to co-develop synthetic genes for engineered cell programs. The collaboration leverages Twist's silicon-based DNA synthesis technology for bioindustrial manufacturing and pharmaceutical applications.
• November 2024: Codex DNA (now Telesis Bio) introduced the BioXp Select DNA Assembly Kit, a customizable gene synthesis solution for rapid, automated construction of synthetic genes and genetic circuits, enabling same-day synthesis and cloning for synthetic biology research.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.